DE602004029767D1 - DETECTION, MONITORING AND TREATMENT OF CANCER - Google Patents

DETECTION, MONITORING AND TREATMENT OF CANCER

Info

Publication number
DE602004029767D1
DE602004029767D1 DE602004029767T DE602004029767T DE602004029767D1 DE 602004029767 D1 DE602004029767 D1 DE 602004029767D1 DE 602004029767 T DE602004029767 T DE 602004029767T DE 602004029767 T DE602004029767 T DE 602004029767T DE 602004029767 D1 DE602004029767 D1 DE 602004029767D1
Authority
DE
Germany
Prior art keywords
detection
treatment
cancer
monitoring
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029767T
Other languages
German (de)
Inventor
James Ironside Bruce
Sotiris Missailidis
Katalin Eszter Borbas
Catia Sofia Ferreira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Open University
Original Assignee
Open University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Open University filed Critical Open University
Publication of DE602004029767D1 publication Critical patent/DE602004029767D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

There are disclosed aptamer ligands to MUC1, preferably comprising a sequence selected from: and compounds comprising these aptamers and sequences. There are also disclosed compounds having the structure There are also disclosed methods of treatment, diagnosis, detection and imaging using these compounds, their use in such methods, and their use in the preparation of medicaments and products for such methods.
DE602004029767T 2003-03-10 2004-03-10 DETECTION, MONITORING AND TREATMENT OF CANCER Expired - Lifetime DE602004029767D1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305422.8A GB0305422D0 (en) 2003-03-10 2003-03-10 Detection, monitoring and treatment of cancer
PCT/GB2004/001028 WO2004081574A2 (en) 2003-03-10 2004-03-10 Detection, monitoring and treatment of cancer

Publications (1)

Publication Number Publication Date
DE602004029767D1 true DE602004029767D1 (en) 2010-12-09

Family

ID=9954463

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029767T Expired - Lifetime DE602004029767D1 (en) 2003-03-10 2004-03-10 DETECTION, MONITORING AND TREATMENT OF CANCER

Country Status (7)

Country Link
US (1) US20070160526A1 (en)
EP (4) EP2209000A3 (en)
AT (1) ATE486284T1 (en)
CA (1) CA2518783A1 (en)
DE (1) DE602004029767D1 (en)
GB (1) GB0305422D0 (en)
WO (1) WO2004081574A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007023766A1 (en) * 2005-08-23 2007-03-01 National University Corporation Gunma University Singlet oxygen generators having silicon-containing substituents
GB2437727B (en) * 2006-05-04 2011-04-20 Univ Open Aptamers directed to MUC1
WO2007128109A1 (en) * 2006-05-04 2007-11-15 University Health Network Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac)
JP5841046B2 (en) * 2009-04-08 2016-01-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Human protein scaffold with controlled serum pharmacokinetics
KR101189790B1 (en) * 2009-06-01 2012-10-11 성균관대학교산학협력단 Nucleic Acid Aptamer Capable of Specifically Binding to Pancreatic Cancer Cell or Tissue and Use Thereof
CN103160513B (en) * 2011-12-16 2015-07-01 中国医学科学院基础医学研究所 MUC1 protein nucleic acid aptamer, complex, composition and purposes thereof
EP2639227A1 (en) * 2012-03-14 2013-09-18 Bracco Imaging S.p.A A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents
KR20220139425A (en) 2012-07-13 2022-10-14 웨이브 라이프 사이언시스 리미티드 Chiral control
WO2015117201A1 (en) 2014-02-05 2015-08-13 Deakin University Aptamer construct
CN105879027B (en) * 2014-05-16 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 Nucleic acid ligand modified gold nano-graphene composite material and preparation method and application thereof
US10081776B2 (en) 2015-05-11 2018-09-25 Northwestern University Cyclen friction modifiers for boundary lubrication
WO2020230047A1 (en) * 2019-05-15 2020-11-19 Affinito Alessadra Aptamers against glioblastoma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915958A (en) 1972-05-22 1975-10-28 Icn Pharmaceuticals 6-Substituted purine nucleotides
US3960840A (en) 1972-12-29 1976-06-01 University Of Illinois Foundaton Fluorescent derivatives of adenine-containing compounds
US4038480A (en) 1973-09-17 1977-07-26 Icn Pharmaceuticals, Inc. 6-aminocarbonyl purine 3',5'-cyclic nucleotides
FR2287910A1 (en) 1974-10-15 1976-05-14 Asahi Chemical Ind NUCLEOTID DERIVATIVES AND PROCESS FOR THE PREPARATION OF THE SAME
US3968101A (en) 1974-12-20 1976-07-06 Icn Pharmaceuticals, Inc. 8-Substituted cyclic nucleotides by free radical alkylation and acylation
US4048307A (en) 1974-12-26 1977-09-13 Asahi Kasei Kogyo Kabushiki Kaisha Cyclic adenosine monophosphate 8-substituted derivatives
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6268350B1 (en) * 1997-10-23 2001-07-31 Biocrystal Ltd. Polynucleotides for inhibiting metastasis and tumor cell growth
US6418338B1 (en) * 1998-02-06 2002-07-09 Phylatron Ltd. Method for detecting and surgically removing lymphoid tissue involved in tumor progression
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
TR200101775T2 (en) * 1998-12-18 2002-07-22 Dupont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6251616B1 (en) * 1999-01-14 2001-06-26 Biocrystal Ltd. Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response
AU2001234478A1 (en) 2000-01-21 2001-07-31 Mallinckrodt, Inc. Chelating agents and method for their use as tandem metal chelators and hydrophilic spacers for medical diagnosis and therapy
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US6376190B1 (en) * 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
AU2002239468A1 (en) 2000-10-31 2002-05-27 Bracco International B.V. Conjugates of an antioxidants with metal chelating ligands
EP1381392A4 (en) 2001-04-24 2005-03-23 Ts Corp Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same
EP1552002A4 (en) * 2002-06-18 2006-02-08 Archemix Corp Aptamer-toxin molecules and methods for using same

Also Published As

Publication number Publication date
EP1601970B1 (en) 2010-10-27
CA2518783A1 (en) 2004-09-23
EP1601970A2 (en) 2005-12-07
ATE486284T1 (en) 2010-11-15
EP2209000A3 (en) 2010-10-27
GB0305422D0 (en) 2003-04-16
WO2004081574A3 (en) 2004-12-16
EP1806585A1 (en) 2007-07-11
WO2004081574A2 (en) 2004-09-23
EP2209000A2 (en) 2010-07-21
US20070160526A1 (en) 2007-07-12
EP2287613A2 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
DE60303238D1 (en) Pyrimidine-acetic acid derivatives suitable for the treatment of CRTH2-related diseases
ATE527241T1 (en) PYRIDIAZINONE DERIVATIVES FOR THE TREATMENT OF TUMORS
DE602004028763D1 (en) TE FOR THE TREATMENT OF VIRUS DISEASES
DE602004026891D1 (en) TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C
ATE424386T1 (en) PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN-MEDIATED DISEASES
ATE453653T1 (en) PLATINUM COMPLEXES FOR THE TREATMENT OF TUMORS
ATE486284T1 (en) DETECTION, MONITORING AND TREATMENT OF CANCER
CY1106386T1 (en) SUBSTITUTED 3-PYRROLIDINE-INDOLE DERIVATIVES
DE602006007481D1 (en) 5-AMINO-4-HYDROXY-7- (IMIDAZOE1,2-ATPYRIDIN-6-YLMETHYL) -8-METHYLNONAMID DERIVATIVES AND RELATED COMPOUNDS AS RENININHIBITORS FOR TREATING BLOOD HIGH PRESSURE
ATE448232T1 (en) SUBSTITUTED HETEROCYCLES
CY1111022T1 (en) NEW PHARMACEUTICAL COMBINATIONS FOR THE RESPIRATORY DISEASE TREATMENT
NO994932L (en) Mixtures and Methods for Treating and Diagnosing Breast Cancer
EA200801580A1 (en) NEW PIRININOD DERIVATIVES AND METHOD FOR THEIR PRODUCTION
CY1111256T1 (en) AZADICYCLOKTAN-3-ONE PRODUCTS AND THEIR USE
ATE443704T1 (en) PYRIDOPYRIMIDINONE FOR THE TREATMENT OF CANCER DISEASES
DE602004003952D1 (en) SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS SUITABLE FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
DE602006003094D1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCHINOLINE DERIVATIVES FOR THE TREATMENT OF BARRENESS
DE602005019341D1 (en) System for the treatment of sterilization cassettes with visual dual-code reader
ATE424823T1 (en) 4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROCINOLINE DERIVATIVES AS MEDICINAL PRODUCTS FOR THE TREATMENT OF INFERTILITY
DE602005015434D1 (en) MEANS FOR THE TREATMENT OF PSYCHONEUROTIC DISEASES
MXPA01010186A (en) Compositions and methods for the treatment and diagnosis of breast cancer.
ITBO20030050A1 (en) MACHINE FOR THE TREATMENT OF PHARMACEUTICAL PRODUCTS.
DE502005002104D1 (en) Hesperidin for the treatment of epilepsy
FR2860234B1 (en) NEW THIOXYLOSE DERIVATIVES 666
DE60319240D1 (en) Use of ligands of CD52 antigen for the treatment of solid tumors and bone cancers